Biotech: Making Money the Old-Fashioned Way

At the January 1999 Hambrecht & Quist meeting, investors were hearing a new message from biotechs: the Millennium-ization of the industry. Platform companies are promising to leverage their technologies much more aggressively for many more customers. They'll identify their assets, sell them, and sell them again.

Given that most of the January 1999 Hambrecht & Quist conference was given over to biotechnology—whose investment popularity has reached new lows—the sheer number of attendees was breathtaking: more than 4400 registrants, about 1000 more than last year. In part, the growth in attendance stems from the growth in the number of companies presenting: the more presenters (about 300 firms this year, up from 220 three years ago), the more analysts from each investment firm, company representatives, VCs, and the various PR tag-alongs.

But for those investors who were listening, presenters were delivering a new message: leverage. In the mid-1990s, biotechs sold Wall Street on the concept that drug companies, looking for faster...

More from Business Strategy

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By 

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.